Premium
Factors affecting cardiolipin antibody assays: modification with polyethylene glycol compound
Author(s) -
Kilpatrick David C.
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00532.x
Subject(s) - polyethylene glycol , cardiolipin , antibody , chemistry , medicine , pharmacology , virology , chromatography , immunology , biochemistry , membrane , phospholipid
Anti‐cardiolipin antibody (aCL) measurement is only semi‐reproducible, and current assays detect irrelevant as well as clinically significant antibodies. Factors found to influence results included the source of the enzyme‐linked immunoabsorbent assay (ELISA) plate, and its pre‐treatment with solvents; the nature of the blocking solution; and the composition of the diluent used for reagents. Fetal calf serum (FCS) in the diluent appeared to reduce non‐specific (clinically irrelevant) binding and was not simply a source of β 2 ‐glycoprotein‐1 (β 2 GP1). A polyethylene glycol compound was found to be an effective blocking agent, and its use enhanced the discrimination between positive and negative samples. A high level of variation may be inherent in aCL‐ELISA methodology, but the use of polyethylene glycol compound appeared to be a helpful modification.